Subject Index

Acromegaly
- ectopic tumors 208, 209
- glucose intolerance 208
- growth hormone assays, see Growth hormone
- insulin-like growth factor-I and binding protein assays, see Insulin-like growth factors
- pathophysiology 200, 202
- pituitary imaging 208
- prolactin tests 207, 208

Active renin (ARE), mineralocorticoid function assessment 376

Adrenal gland
- adrenocortical tumors, gas chromatography-mass spectrometry of urinary steroids 442
- adrenocorticotropin stimulation tests
  - infusion tests 389, 390
  - long tests using depot transcortin 390
- low-dose short test
  - diagnostic value 389
  - evaluation 389
  - purpose 387, 389
  - technique 389
- short test
  - diagnostic value 386, 387
  - evaluation 384, 385
  - technique 383, 384
- androgen assays and metabolism 380, 381
- autoantibody detection 383
- cortex basal function tests
  - cortisol precursors and metabolites 372–375
  - progestins 375, 377, 378
- dexamethasone suppression testing
  - overnight high-dose test 399
  - overnight test 397, 398
  - perfusion test 398
  - purpose 396, 397
  - standard 6-day low-dose, high-dose test 398, 399
- imaging
  - angiography 405
  - computed tomography 403, 404
  - intravenous urography 402
  - magnetic resonance imaging 404
  - plain radiographs 402
  - ultrasound
    - diagnostic value 64
    - differential diagnosis 403
    - normal findings 64
    - technical requirements 63, 64
- insufficiency
  - cortical insufficiency causes 406, 407, 409
  - gas chromatography-mass spectrometry of urinary steroids 432, 433, 442
- insulin tolerance test 392, 393
- lysine 8 vasopressin test 393, 394
Adrenal gland (continued)
medullary function testing
basal state 399–402
dynamic testing 402
metapyrone test 394–396
mineralocorticoid function assessment 376, 380
obesity changes 501, 502
preterm diagnosis, fetal adrenal insufficiency 405, 406
scintigraphy
cortex
indications 87
interpretation 88
patient preparation 87
radiopharmaceuticals 87
side effects 88
technique 88
medulla
indications 82–84
interpretation 85, 86
m-iodobenzylguanidine as tracer 78, 79, 81, 404, 405
m-iodobenzylguanidine uptake 81, 82
neuroblastoma 79, 80
patient preparation 84
pheochromocytoma 80, 81
side effects 86
technique 85
tracer alternatives to
m-iodobenzylguanidine 86, 87
sodium balance studies 380
steroid excess diagnosis
ambiguous genitalia 416, 417
Cushing’s syndrome 408
differential diagnosis 407, 408
hyperaldosteronism 408, 410, 411
hyperandrogenemia 411–416
venous sampling 405
Adrenocorticotropin (ACTH)
anorexia nervosa levels 491
assay 382
corticotropin-releasing hormone stimulation test, see Corticotropin-releasing hormone
lysine 8 vasopressin test 393, 394
metapyrone test 394–396
pheochromocytoma, see
Pheochromocytoma stimulation tests
infusion tests 389, 390
long tests using depot tetracosactrin 390
low-dose short test
diagnostic value 389
evaluation 389
purpose 387, 389
technique 389
preterm infants 455, 456
short test
diagnostic value 386, 387
evaluation 384, 385
technique 383, 384
Adrenoleukodystrophy (ALD)
gene mutations 382
very-long-chain fatty acid assay in diagnosis 382
Aldosterone
assays
metabolites 226
overview 376
precursors 226, 229
hyperaldosteronism diagnosis 408, 410, 411
metabolism 376
normal levels of hormone, precursors, and metabolites
plasma 226–228
urine 226–228
sodium loss disorders
aldosterone and cortisol synthesis defects 229, 231
pseudohypaldosteronism type I 232
transient pseudohypaldosteronism type I 232, 233
sodium regulation 224
sodium retention disorders
glucocorticoid-suppressible aldosteronism 234, 235
pseudohypaldosteronism type II 237
synthesis 428
Alkaline phosphatase, bone formation markers 462, 464
Ambiguous genitalia
causes 416
diagnosis 416, 417
diagnostic flow chart 526
gas chromatography-mass spectrometry of urinary steroids 432, 433

Androgens
adrenal assays and metabolism 380, 381
biosynthetic genes and mutations 351
normal male values in childhood and puberty 344
obesity changes 499–501
ovarian endocrine function assessment 365
receptor structure and mutations 350, 351
regulation of release in females 360
synthesis 428
testicular function assessment
androgen-binding studies in vitro 350
basal plasma androgen determinations
assays 343, 344
infants 343, 344
puberty 345, 346
human chorionic gonadotropin stimulation testing 347
urinary steroid metabolite assays 348

Androstenedione, assays and metabolism 381

Anorexia nervosa (AN)
amenorrhea 488, 489
diagnosis 488
gonadotropin response 487–490
growth hormone system perturbation 493, 494
hypogonadism pathophysiology 487–490
hypothalamic-pituitary-adrenal axis perturbations 491, 492
prolactin levels 495
skeletal changes 494, 495
thyroid function perturbation 492, 493

Anovulation, assessment 369
Anti-Müllerian hormone (AMH), testicular function assessment 349

Arginine infusion test
diagnostic value 330
interpretation 330

intravenous glucose tolerance test 330
purpose 319, 329
technique 329, 330
tolbutamide test 331

Arginine tolerance test (ATT), growth hormone stimulation testing
acromegaly 204
arginine with growth hormone-releasing hormone stimulation test 123
arginine with insulin tolerance test 120
principles 118, 119

Arginine vasopressin (AVP) assays 216
disorders, see Diabetes insipidus;
Syndrome of inappropriate secretion of antidiuretic hormone
osmoregulatory system 212
regulation of release
osmoreceptors 213
thirst 214
volume 213, 214
renal effects 214, 215
synthesis 212, 213

Bartter-like syndromes, features 233

Beta cell
blood supply 261
electrical coupling of glucose and insulin release
ATP-sensitive potassium channels 262, 264, 265, 267–272
calcium signaling 263, 264
phases of release 262, 264
gene defects and disease 266
hyperinsulinism in infancy, features 276, 277
innervation 261

Beta cell function assessment
arginine infusion test
diagnostic value 330
interpretation 330
intravenous glucose tolerance test 330
purpose 319, 329
technique 329, 330
tolbutamide test 331
diagnostic flow chart for hyperglycemia 523
bone densitometry with quantitative computed tomography 476
Congenital adrenal hyperplasia (CAH) gas chromatography-mass spectrometry of urinary steroids 432, 433 hypertensive forms 234 Corticotropin-releasing hormone (CRH) anorexia nervosa levels 492 stimulation test diagnostic value 391, 392 evaluation 391 preterm infants 456 purpose 391 standardization 392 technique 391 Cortisol adrenocorticotropin stimulation tests, see Adrenocorticotropin anorexia nervosa levels 491 cortisone conversion 373 diagnostic flow chart for hypercortisolism 528 metabolities and assays 373–375 preterm infant assessment 455 pulsatile secretion 372, 373 synthesis 428 synthesis defects and sodium loss 229, 231 testicular function assessment 347, 348 Cryptorchidism, diagnostic flow chart 525 Cushing’s syndrome diagnosis 408 gas chromatography-mass spectrometry of urinary steroids 442 Dehydroepiandrosterone (DHEA) assays and metabolism 380, 381 synthesis 428 Delayed puberty clomiphene stimulation testing in males 349 diagnostic flow chart 524 female assessment 367, 368 Denaturing gradient gel electrophoresis (DGGE), principles 40 Denaturing high-performance liquid chromatography, heteroduplex detection 40, 41 Dexamethasone suppression test overnight high-dose test 399 overnight test 397, 398 perfusion test 398 purpose 396, 397 standard 6-day low-dose, high-dose test 398, 399 Diabetes insipidus definition 215 diagnosis arginine vasopressin assay 216 dehydration test 216–219 flow chart for polyuria 519 osmolality of plasma and urine 216 short desmopressin test 219, 220 urine volume 215 genetic testing 221 infants and young children 221 tumor imaging 220, 221 Diabetes mellitus, see also Beta cell function assessment types 325 Diazoxide, hyperinsulinism in infancy management 280, 281 Dihydrotestosterone, see Androgens DNA extraction from blood 42–44 DNA cloning positional cloning 33 strategies 31–33 DNA sequencing automation 41, 42 polymerase chain reaction products 39, 40 Sanger method 41 L-Dopa, growth hormone stimulation testing 121 Dopamine assays 399, 400 growth hormone stimulation testing 204, 205 neuroblastoma diagnosis 401, 402 normal values by age 400, 401
Energy expenditure, types 482, 483
Epinephrine
  assays 399, 400
  neuroblastoma diagnosis 401, 402
  normal values by age 400, 401
Estrogens
  ovarian endocrine function assessment 364
  regulation of release in females 358, 359
  synthesis 428
Exercise testing, growth hormone
  stimulation testing 116–118
False-positive rate, hormone assays 27
Follicle-stimulating hormone (FSH)
  levels in normal girls 362
  normal male values in childhood and puberty 344
  ovarian endocrine function assessment 361–363
  regulation of release in females 357
  testicular function assessment 348, 349
Gas chromatography-mass spectrometry (GC-MS)
  advantages in steroid profiling 427, 428
  plasma steroid profiling using isotope dilution
    advantages 443
    prospects 446
    steroid levels and clinical utility 445
  urinary steroid profiling
    adrenal insufficiency 432, 433, 442
    adrenocortical tumors 442
    advantages 446
    ambiguous genitalia 432, 433
    congenital adrenal hyperplasia 432, 433
    Cushing’s syndrome 442
    enzyme defects and indications 432, 433
    normal values by age 434–440
    polycystic ovary syndrome 442
    precocious puberty 432, 433
    sample preparation 429–432
    treatment monitoring, 21-hydroxylase deficiency 441
    virilization 432, 433
Genetic testing, see Molecular genetic testing
Ghrelin
  body mass regulation 482
  growth hormone stimulation testing 124
Glucagon
  beta cell function assessment
    diagnostic value 329
    interpretation 329
    purpose 319, 328
    technique 328, 329
  growth hormone stimulation testing 121
  hyperinsulinism in infancy management 282
  provocation test for hypoglycemia 308
Glucokinase, hyperinsulinism in infancy mutations 284
Gluconeogenesis, evaluation with tolerance tests 309, 310
Glucose tolerance tests, see Intravenous glucose tolerance test; Oral glucose tolerance test
Glutamate dehydrogenase, hyperinsulinism in infancy mutations 284
Gonadotropin-releasing hormone (GnRH), growth hormone stimulation testing 205
  regulation of release in females 357
  stimulation testing in females 362, 363
  testicular function assessment 349
Growth hormone (GH)
  adrenal function 501, 502
  age-related changes in secretion 150, 151, 456, 457
  anorexia nervosa perturbation 493, 494
  assays
    basal levels 202, 203
    immunofunctional assay 113
    normalization of data 110, 111
    radioimmunoassay 112, 138, 139
    radioreceptor assay 113
    standardization 108, 113
  bone density changes 504
  disorders, see Acromegaly; Growth hormone deficiency
  ectopic tumor, secretion 208, 209
  half-life estimation 132
  insulin-like growth factor system
interactions 168, 169, 180, 181
therapy monitoring 189–192
insulin resistance 502–504
obesity perturbations
  binding protein changes 498, 499
  metabolic and nutritional factors
    influencing secretion 497, 498
    overview 496
  spontaneous secretion 496, 497
  stimulated secretion 497
pituitary adenoma imaging 208
preterm infant evaluation 457
pulsatile secretion and biological effects 129–131
regulation of secretion 113, 114, 129, 130, 168, 169, 201, 202, 496
secretion versus sensitivity 151
spontaneous secretion analysis
  acromegaly 203
deconvolution techniques 136, 137
distribution techniques 136
findings
  day versus night values 144, 145
  healthy adults 149
  healthy children of normal or short stature 141–143
  plasma concentrations over 24 h 146–148
  integrated versus discrete sampling 132–134
overview 109, 110
pulsatility versus secretion rate 131, 132
pulse detection 135, 136
reproducibility of assays 139, 140
sampling interval 132
sampling period 134, 135
time series analysis 135
stimulation testing
  arginine-growth hormone-releasing hormone test 123
  arginine-insulin tolerance test 120
  arginine tolerance test 118, 119, 204
  clonidine test 120, 121
  L-dopa test 121
dopamine test 204, 205
  exercise test 116–118
ghrelin test 124
glucagon test 121
growth hormone-releasing hormone test 122, 123, 204
growth hormone-releasing peptide test 124
insulin tolerance test 119, 120, 204
  normality of response 124
overview 114–116
preparation for testing 116
pyridostigmine-growth hormone-releasing hormone test 123
sex steroid priming 121, 122
thyrotropin-releasing hormone 205
suppression testing
  oral glucose tolerance test 205, 209
  somatostatin test 206
thyroid function 504
urine assays
  acromegaly 203, 204
  advantages 163
  circulating hormone correlations 161, 163
  intraday variation 162
  limitations 161, 162
  monitoring of growth hormone therapy 163
  normal values 161
overview 110, 160
  puberty effects 162, 163
  renal metabolism 160
  reporting of results 162
Growth hormone deficiency (GHD)
biochemical findings 108, 109
diagnosis
  criteria 107, 108
  flow chart 517
pathophysiology 107
response to growth hormone therapy 151, 152
Growth hormone-releasing hormone (GHRH), growth hormone stimulation testing
  acromegaly 204
  arginine-growth hormone-releasing hormone test 123
  principles 122, 123
Growth hormone-releasing hormone (GHRH), growth hormone stimulation testing (continued)
pyridostigmine growth hormone-releasing hormone test 123
Growth hormone-releasing peptides (GRPs), growth hormone stimulation testing 124

Hirsutism, see Virilization
Homovanillic acid (HVA)
neuroblastoma diagnosis 401, 402
normal values by age 400
Hormone assays, see also specific hormones
bioassays 2
diagnostic error 27, 28
good medical practice 1
immunoassays
agglutination assay 13, 14
antibody production 3, 4
antigen production 4
applications 15
calibration curve fitting 12, 13
competitive versus noncompetitive 5–7
enzyme immunoassay 8, 9
labeling of assay components and
detection systems 7–10
microarray chip technology 14, 15
nephelometry 14
principles 5
radioimmunoassay 7
separation techniques for heterogenous
assays 9, 11
surface plasmon resonance 14
technical trends 14
in situ assays 3
interpretation 26, 27
performance and quality management
clinical validation 23, 24
preanalytical phase 16
quality assurance 20, 21, 23
reference interval determination
prerequisites 24
statistical analysis 25
technical validation 17–20
radioreceptor assays 2, 3

Human chorionic gonadotropin (hCG)
gonadal development, role 357
stimulation testing in testicular function
assessment
androgen responses 347
protocols 346
sex hormone-binding globulin
responses 347
L-3-Hydroxyacyl-CoA dehydrogenase,
hyperinsulinism in infancy mutations
284, 285
Hypercalcemia
diagnostic flow chart 521
differential diagnosis 256
Hyperglycemia, see Beta cell function
assessment
Hyperinsulinemic clamp studies, beta cell
function assessment 333, 334
Hyperinsulinism in infancy (HI)
acute insulin response testing 277, 278
animal models 278, 279
ATP-sensitive potassium channel
gene mutations 271–276
structure and regulation 265, 267–271
beta cell features 276, 277
clinical features 260
glucokinase mutations 284
glutamate dehydrogenase mutations 284
L-3-Hydroxyacyl-CoA dehydrogenase
mutations 284, 285
incidence 261
prospects for study 285
sequelae 259, 260
treatment
diazoxide and analogs 280, 281
glucagon 282
nifedipine 281, 282
somatostatin 283
Hyperthyroidism
diagnostic flow chart 516
Graves’ disease 104
hormone assays in diagnosis 104, 105
Hypocalcemia
diagnostic flow chart 521
differential diagnosis 255
Hypoglycemia, see also Hyperinsulinism in
infancy
diagnosis
blood sampling during event 301
diagnostic fast 301, 302, 304–308
familial hyperinsulinism 313
flow chart 522
glucagon provocation test 308
gluconeogenesis evaluation with
tolerance tests 309, 310
histology of pancreatic tissue 311
history 295, 296
hypocaloric ketogenic diet 309
imaging for tumors 311
inborn errors of metabolism evaluation
enzyme assays 312, 323
flux measurements 312
genetic testing 313, 314
infants and children 297–300
isotope turnover studies 310, 311
long-chain fat loading 309
neonatal hypoglycemia 296, 297, 315
phenylpropionate loading 308
physical examination 295, 296
prenatal diagnosis 314

glucose homeostasis mechanisms 293, 294
glucose measurement 294, 295
neonatal hypoglycemia management
297, 298
sequelae 293

Hypothyroidism
congenital hypothyroidism
causes 514
diagnostic flow chart 515
genetic testing 101, 103
diagnostic flow chart 515
Hashimoto’s thyroiditis, diagnosis 101, 102
hormone assays in diagnosis 100, 101
neonatal diagnostic workup 101, 102
subclinical hypothyroidism 102, 103

Immunooassays, hormones
agglutination assay 13, 14
antibody production 3, 4
antigen production 4
applications 15
calibration curve fitting 12, 13

competitive versus noncompetitive 5–7
enzyme immunoassay 8, 9
labeling of assay components and
detection systems 7–10
microarray chip technology 14, 15
nephelometry 14
principles 5
radioimmunoassay 7
separation techniques for heterogenous
assays 9, 11
surface plasmon resonance 14
technical trends 14

Inhibins
ovarian endocrine function assessment
364
regulation of release in females 359
testicular function assessment 350
types 359

Insulin, see also Beta cell function
assessment; Hypoglycemia
C-peptide assay 318, 320, 321
fasting concentrations 320, 321
gene transcription 264, 265
half-life 318
hyperinsulinism, see Hyperinsulinism in
infancy
insulin-like growth factor system
interactions 181, 182
resistance in obesity 502–504
sensitivity tests
frequent-sampling intravenous glucose
tolerance test 334
hyperinsulinemic clamp studies 333, 334
indices 334–336
synthesis, see Beta cell

Insulin tolerance test (ITT)
adrenal function testing
diagnostic value 393
evaluation 393
preterm infants 456
purpose 392
technique 392, 393

growth hormone stimulation testing
acromegaly 204
arginine and insulin tolerance test 120
principles 119, 120
Insulin-like growth factors (IGFs)
anorexia nervosa perturbation 493, 494
assays
  binding protein interference 171, 172
  formats 171
  IGF-I 173, 174
  IGF-II 174
  normal ranges 175–179
  SDS computation 178–179
  separation from binding proteins
    acid-ethanol extraction 172, 173
    functional separation 173
    size exclusion chromatography 172
  stability 174, 175
binding proteins
  assay of IGFBP-3 174
  binding affinities 167, 172
  functions 169, 170
  IGFBP-3 level correlation with IGF
    levels 170, 171
  IGFBP-3 normal values 175, 178
  regulation 170
  related proteins 167, 168
  stability 174, 175
  synthesis 168
  types 167
developmental expression 457
factors affecting serum levels of growth
  factors and binding proteins
  circadian rhythm 180
  growth hormone 180, 181
  illness 182
  insulin 181
  kidney function 182, 183
  liver function 182
  nutrition 182
  overview 179, 180
  post-aggression syndrome 182
  sex steroids 181
  thyroid hormone 181
growth hormone
deficiency evaluation 110, 111, 166, 183–189
  excess evaluation 189, 206, 207
  interactions 168, 169, 180, 181
  therapy monitoring 189–192
obesity changes 498
preterm infant evaluation 457
receptors 169
regulation of secretion 166, 168
structures 166, 167
synthesis 168
Intrauterine growth retardation (IUGR),
  endocrine consequences 483, 486
Intravenous glucose tolerance test (IGTT)
  arginine infusion 330
  diabetes criteria 324, 325
  diagnostic values 327, 328
  frequent-sampling intravenous glucose
tolerance test 334
  interpretation 326
  phases of insulin secretion 326, 327
  purpose 319
  technique 325
Iodine
  radioisotope scintigraphy 100
  thyroid requirements 68, 69
  urine assays 99, 100
Kallmann’s syndrome, gene mutations 352
Leptin
  body mass regulation 481, 482
  hypothalamic-pituitary-adrenal axis
    interactions 491, 492
  puberty, role 488
Liddle’s syndrome, features 236, 237
Linkage analysis, principles 33, 34, 36
Luteinizing hormone (LH)
  anorexia nervosa levels 487–490
  levels in normal girls 362
  normal male values in childhood and
    puberty 344
  ovarian endocrine function assessment
    361–363
  precocious puberty and activating
    mutations in receptor 352
  regulation of release in females 357
  testicular function assessment 348,
    349
Luteinizing hormone-releasing hormone,
  see Gonadotropin-releasing hormone
Lysine 8 vasopressin test
  diagnostic value 394
Magnetic resonance imaging (MRI), adrenal gland 404

Metapyrone test
diagnostic value 396
evaluation 395, 396
preterm infants 456
purpose 394, 395
technique 395

Molecular genetic testing, see also specific techniques
gene defects and diseases 45
inborn errors of metabolism 313, 314
indications 44, 49
overview 30
terminology 46–48

Negative predictive value (NPV), hormone assays 27

Neuroblastoma
catecholamine levels in diagnosis 401, 402
dopamine levels in diagnosis 401, 402
homovanillic acid in diagnosis 401, 402
scintigraphy 79, 80
vanillylmandelic acid in diagnosis 401, 402

Nifedipine, hyperinsulinism in infancy
management 281, 282

Norepinephrine
assays 399, 400
neuroblastoma diagnosis 401, 402
normal values by age 400, 401

Obesity
diagnostic flow chart 519

epidemiology 495
etiology in children 495, 496
growth hormone system perturbations
binding protein changes 498, 499
insulin-like growth factor changes 498
metabolic and nutritional factors
influencing secretion 497, 498
overview 496
spontaneous secretion 496, 497
stimulated secretion 497
leptin system mutations 481, 482
polycystic ovary syndrome 499, 500
sex hormone perturbation 499–501

Oral glucose tolerance test (OGTT)
beta cell function assessment
diabetes criteria 321–323
diagnostic value 323, 324
interpretation 323
purpose 319
technique 322
growth hormone supression testing 205, 209

Osteocalcin, bone formation marker 462, 464

Ovaries
assessment of endocrine function
androgens 365
anovulation 369
blood sampling for assays 366, 367
clinical assessment 361
delayed puberty 367, 368
estrogens 364
follicle-stimulating hormone 361–363
gonadotropin-releasing hormone stimulation test 362, 363
hypothalamo-pituitary-gonadal axis testing 363, 364
inhibins 364
luteinizing hormone 361–363
ovarian failure 367, 368
precocious puberty 367
progesterone 364
prolactin 362
sex-hormone-binding globulin 365, 366
virilization 368, 369

Subject Index
Subject Index

Ovaries (continued)
  hypothalamo-pituitary-gonadal axis
    fetal and prepubertal development 357
  regulation of release
    activins 359
    androgens 360
    estrogens 358, 359
    follicle-stimulating hormone 357
    gonadotropin-releasing hormone 357
    inhibins 359
    luteinizing hormone 357
    progesterone 359
    prolactin 357, 358
    sex-hormone-binding globulin 360
  ultrasound
    diagnostic values 61
    normal findings 60, 61
    technical requirements 58, 60
    transvaginal sonography 61

Parathyroid hormone (PTH)
  calcium regulation 245
  evaluation
    calcium levels in serum 245
    cyclic AMP levels in urine and plasma
    basal urinary excretion 250
    parathyroid hormone stimulation
      test 250, 252
      rationale 249, 250
    phosphate levels in serum 245
    renal phosphate reabsorption 246
  serum assays
    formats 246, 247
    immunoradiometric assay 248
    intact hormone 247–249
    two-site chemiluminometric assay 249
  regulation of secretion 245
  synthesis 244, 245

Parathyroid hormone-related protein (PTHrP)
  assays 253
  fetal development, role 252
  lactation, role 252, 253
  splice variants 253

Parathyroid scintigraphy
  indications 77
  radiopharmaceuticals 77
  side effects 78
  technique 78

Phenylpropionate loading, hypoglycemia
  diagnosis 308

Pheochromocytoma
  markers 400, 401
  scintigraphy 80, 81
  syndromes 401
  venous sampling 405

Plasma renin activity (PRA)
  determination 225, 226
  mineralocorticoid function assessment 376

Polycystic ovary syndrome (PCOS)
  gas chromatography-mass spectrometry
    of urinary steroids 442
  obesity 499, 500

Polymerase chain reaction (PCR)
  gel electrophoresis of products 38, 39
  primers 37
  principles 35–37
  sample preparation 42–44
  sequencing of products 38, 39
  thermal cycling 37, 38

Positive predictive value (PPV), hormone assays 27

Potassium channel, ATP-dependent hyperinsulinism in infancy
  gene mutations 271–276
  knockout mouse models 278, 279
  insulin release regulation 262, 264
  structure and regulation 265, 267–271

Precocious puberty
  diagnostic flow chart for girls 527
  female assessment 367
  gas chromatography-mass spectrometry
    of urinary steroids 432, 433
  male 352

Premature infants
  adrenal steroids
    adrenocorticotropic hormone stimulation testing
      455, 456
    corticotropin-releasing hormone stimulation test 456
cortisol assays 455
insulin tolerance test 456
metapyrone test 456
normal physiology 454
epidemiology 450
growth hormone axis evaluation 456–458
sequelae 450, 483, 486
thyroid hormone
assays of thyroid status 452–454
congenital hypothyroidism 452
normal physiology 94, 95, 451
transient hypothyroidism 452
transient hypothyroxinemia 451, 452
Prevalence, calculation 27
Progestosterone
ovarian endocrine function assessment 364
regulation of release in females 359
Progestins, assay 375, 377, 378
Prolactin (PRL)
anorexia nervosa perturbation 495
assays 207
ovarian endocrine function assessment 362
regulation of release in females 357, 358
regulation of secretion 202
Prolactinoma
multiple hormone secretion 208
pathophysiology 200, 202
Pseudohermaphroditism, causes in males 345
Puberty, see also Delayed puberty;
Precocious puberty
leptin, role 488
male stages 342
Pyridostigmine, growth hormone
stimulation testing 123
Radioimmunoassay
arginine vasopressin 216
growth hormone 112, 138, 139
principles 7
Reference interval, determination for
hormone assays
prerequisites 24
statistical analysis 25
Renin, see Active renin; plasma renin
activity
Restriction fragment length polymorphism
(RFLP), principles 34, 35
Rickets
diagnostic flow chart 520
differential diagnosis 253, 254
RNA, sample preparation 44
Scintigraphy
adrenal gland
cortex
indications 87
interpretation 88
patient preparation 87
radiopharmaceuticals 87
side effects 88
technique 87, 88
medulla
indications 82–84
interpretation 85, 86
m-iodobenzylguanidine as tracer 78, 79, 81, 404, 405
m-iodobenzylguanidine uptake 81, 82
neuroblastoma 79, 80
patient preparation 84
pheochromocytoma 80, 81
side effects 86
technique 85
tracer alternatives to m-iodobenzylguanidine 86, 87
parathyroid
indications 77
radiopharmaceuticals 77
side effects 78
technique 78
thyroid
indications 71–73
interference factors 76, 77
interpretation 75, 76
patient preparation 73, 74
radiopharmaceuticals 69–70, 100
side effects 77
technique 74–75
Subject Index

Sex hormone-binding globulin (SHBG) human chorionic gonadotropin responses in testicular function assessment 347, 348, 349
obesity changes 500 ovarian endocrine function assessment 365, 366 regulation of release in females 360 Single-stranded conformational polymorphism (SSCP), principles of analysis 39, 40
SI units, conversion table 510–512
SRY gene, mutations in gonadal agenesis 352
Testosterone, see Androgens
Thyroglobulin, assays 98
Thyroid gland, see also Hyperthyroidism; Hypothyroidism
anorexia nervosa perturbation 492, 493
autoantibody assays 98, 99
development 67, 68, 93–95
iodine radioisotope studies 100
iodine requirements 68, 69
obesity changes 504
scintigraphy
indications 71–73
interference factors 76, 77
interpretation 75, 76
patient preparation 73, 74
radiopharmaceuticals 69–70, 100
side effects 77
technique 74–75
ultrasound
diagnostic value 54
growth evaluation 97
infants 54, 56
normal findings 53, 54
technical requirements 52
Thyroid hormone
age-specific reference ranges 95–97
assays 95, 96
levels during development 94, 95, 451
regulation of secretion 69
Thyroid-stimulating hormone (TSH)
age-specific reference ranges 95–97
assays 95, 96
hyperthyroidism assays 104
levels during development 94, 95
pituitary adenomas 208
receptor mutation testing 100
Thyrotropin-releasing hormone (TRH)
growth hormone stimulation testing 205
thyroid stimulation testing 97, 98
Tolbutamide challenge test
arginine infusion 331
diagnostic value 332
interpretation 331, 332
purpose 319, 330, 331
technique 331
Ultrasound
adrenal gland
diagnostic value 64
differential diagnosis,
adenomas/carcinomas 403
normal findings 64
technical requirements 63, 64
bone densitometry 476
ovaries
diagnostic value 61
normal findings 60, 61
technical requirements 58, 60
transvaginal sonography 61
reliability in organ size determination 51, 52
testicular function assessment 350
thyroid gland
diagnostic value 54
growth evaluation 97
infants 54, 56
normal findings 53, 54
technical requirements 52
uterus
diagnostic value 57, 58
normal findings 56, 57
technical requirements 56
transvaginal sonography 58
Vanillylmandelic acid (VMA)
neuroblastoma diagnosis 401, 402
normal values by age 400
Vasopressin, see Arginine vasopressin;
Lysine 8 vasopressin test
Virilization
assessment 368, 369
diagnostic flow chart for hirsutism 529
gas chromatography-mass spectrometry
of urinary steroids 432, 433
Vitamin D
assays
1,25-dihydroxyvitamin D 242–244
25-hydroxyvitamin D 241, 242
serum 241
binding protein 241
metabolism 240
receptors 241

Downloaded by: 54.191.40.80 - 9/17/2017 2:14:29 PM